Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02701400 · ClinicalTrials.gov registry record · Phase 2
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
A Phase 2 study of Recurrent Small Cell Lung Carcinoma, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT02701400: Completed Phase 2 study of Recurrent Small Cell Lung Carcinoma, sponsored by Emory University.
NCT02701400 is a Phase 2 study of Recurrent Small Cell Lung Carcinoma that has completed, run by Emory University. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02701400, a Phase 2 study of Recurrent Small Cell Lung Carcinoma, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This randomized clinical trial studies how well tremelimumab and durvalumab with or without radiation therapy works in treating patients with small cell lung cancer that has returned after a period of improvement. Monoclonal antibodies, such as tremelimumab and durvalumab, may limit the ability of tumor cells to grow and spread by enhancing immune function. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tremelimumab and durvalumab together with radiation therapy may lead to improved clinical benefit.
Primary Outcome
Time from initiation of therapy to objective disease progress or death
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- RADIATION Stereotactic Body Radiation Therapy
- RADIATION Hypofractionated Radiation Therapy
- BIOLOGICAL Tremelimumab
Study Locations (2)
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2020-08-07 |
| Phase | Phase 2 |
What the finished NCT02701400 record still lists
NCT02701400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Recurrent Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Durvalumab is the first listed.
NCT02701400 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02701400 about?
NCT02701400 is a clinical study titled "Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer". This randomized clinical trial studies how well tremelimumab and durvalumab with or without radiation therapy works in treating patients with small cell lung cancer that has returned after a period of improvement. Monoclonal antibodies, such as tremelimumab and durvalumab, may limit the ability of t...
What is the current status of trial NCT02701400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-04-14. Estimated completion is 2020-08-07.
What conditions does trial NCT02701400 study?
This clinical trial studies the following conditions: Recurrent Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT02701400?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Stereotactic Body Radiation Therapy (RADIATION), Hypofractionated Radiation Therapy (RADIATION), Tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02701400?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02701400 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02701400's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI